Other IL-23 inhibitors approved for Crohn's disease include risankizumab (Skyrizi) and mirikizumab (Omvoh). Common adverse events (≥3%) with guselkumab in the Crohn's disease trials included ...

as well as approval for Omvoh for managing moderately to severely active Crohn’s disease. Eli Lilly and Company (NYSE:LLY)’s rapid growth in recent years has been largely fueled by the success ...

Lilly’s Omvoh was approved for UC in the United States, Europe and Japan in 2023. Omvoh was approved for CD in the United States in January 2025, while applications are under review in Europe ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the first drug in the class available in both intravenous and subcutaneous ...

In addition to both tirzepatide brands, Lilly expects increasing contributions from four recently launched therapies: Jaypirca, Ebglyss, Omvoh, and Kisunla. It also looks like this big pharma ...

This article delves into the three approved assets in this class – AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Omvoh (mirikizumab), and J&J’s Tremfya (guselkumab) – and explores how ...

Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for ...